التفاصيل البيبلوغرافية
| العنوان: |
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. |
| المؤلفون: |
Artaç, Mehmet, Coşkun, Hasan, Dane, Faysal, Karabulut, Bülent, Korkmaz, Levent, Karaağaç, Mustafa, Çabuk, Devrim, Karabulut, Senem, Faruk Aykan, Nuri, Doruk, Hatice, Avcı, Nilüfer, Turhal, Nazım |
| المصدر: |
Journal of Gastrointestinal Cancer; Sep2016, Vol. 47 Issue 3, p264-272, 9p |
| مستخلص: |
Background: Several chemotherapy regimens using bevacizumab have been developed. Our goal was to investigate regimens that have demonstrated significant clinical activity in patients with metastatic colorectal cancer (mCRC). Materials and Methods: Six hundred and sixty six patients with mCRC who received first-line chemotherapy combination with bevacizumab were studied. Fluoropyrimidine (F) plus irinotecan (I)-based (FI-bev), F plus oxaliplatin (O)-based (FO-bev), and F-based (F-bev) treatment regimens were compared with respect to progression-free survival (PFS) and overall survival (OS). Results: The median PFS of FI-bev ( n = 414) was 10.9 months (95 % CI 10-11.8), of FO-bev ( n = 211) was 9.4 months (95 % CI 8.3-10.4), and of F-bev ( n = 41) was 9.5 months (95 % CI 5.9-13.1) ( p = 0.089). The median OS of FI-bev was 26.3 months (95 % CI 21.7-30.9), of FO-bev was 27 months (95 % CI 24.3-29.7), and of F-bev was 23.3 months (95 % CI 12.7-33.9) ( p = 0.102). In KRAS wild-type patients, the median PFS of FI-bev group was significantly longer than FO-bev group (10.5 vs. 9.1 months, p = 0.006). The FI-bev group had better OS than FO-bev group with borderline significance ( p = 0.058). The FI-bev group had significantly longer OS than F-bev group. Patients who underwent metastasectomy or those with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 had longer PFS and OS independent of the type of chemotherapy regimen. Conclusion: FI-bev may be the preferred frontline regimen for patients with KRAS wild-type mCRC. Metastasectomy and performance score were the strongest positive predictors of OS and PFS regardless of backbone chemotherapy regimen. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Gastrointestinal Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |